Consolidated Statements of Operations and Comprehensive Loss |
12 Months Ended | |||||
|---|---|---|---|---|---|---|
|
Dec. 31, 2025
CNY (¥)
¥ / shares
shares
|
Dec. 31, 2025
USD ($)
$ / shares
shares
|
Dec. 31, 2024
CNY (¥)
¥ / shares
shares
|
Dec. 31, 2023
CNY (¥)
¥ / shares
shares
|
|||
| Net revenues | ¥ 399,914,964 | $ 57,187,079 | ¥ 342,557,920 | ¥ 304,852,971 | ||
| Cost of revenues | 347,632,853 | 49,710,837 | 294,863,867 | 266,131,202 | ||
| Gross profit | 52,282,111 | 7,476,242 | 47,694,053 | 38,721,769 | ||
| Operating expenses: | ||||||
| Sales and marketing expenses (including related party amounts of nil, nil and RMB1,172,706 (US$167,695) for the years ended December 31, 2023, 2024 and 2025, respectively) | 96,214,406 | 13,758,477 | 56,366,433 | 43,678,681 | ||
| General and administrative expenses | 59,729,352 | 8,541,184 | 11,878,335 | 12,314,018 | ||
| Research and development expenses | 12,864,656 | 1,839,621 | 3,002,040 | 3,370,945 | ||
| Impairment loss on long-lived assets | 2,108,517 | 301,514 | 2,238,525 | 1,107,027 | ||
| Impairment loss on long-term investment | 500,000 | |||||
| Total operating expenses | 170,916,931 | 24,440,796 | 73,485,333 | 60,970,671 | ||
| Loss from operations | (118,634,820) | (16,964,554) | (25,791,280) | (22,248,902) | ||
| Other expense, net: | ||||||
| Other income | 496,122 | 70,945 | 1,238,538 | 163,622 | ||
| Other expense | (60,325) | (8,625) | (37,608) | (1,336,595) | ||
| Interest expense (including related party amounts of RMB9,900,417, RMB8,621,249 and RMB8,118,160 (US$1,160,881) for the year ended December 31, 2023, 2024 and 2025, respectively) | (12,885,122) | (1,842,548) | (12,964,584) | (13,849,119) | ||
| Government grants | 152,599 | 21,821 | 189,500 | 321,573 | ||
| Total other expense, net | (12,296,726) | (1,758,407) | (11,574,154) | (14,700,519) | ||
| Loss before income tax | (130,931,546) | (18,722,961) | (37,365,434) | (36,949,421) | ||
| Income tax expense | (375) | (54) | ||||
| Net loss | (130,931,921) | (18,723,015) | (37,365,434) | (36,949,421) | ||
| Accretion to redemption value of mezzanine equity | (81,648,716) | (11,675,611) | (105,969,614) | (108,440,354) | ||
| Less: Net income (loss) attributable to noncontrolling interests | (1,520) | (217) | 25,878 | 1,057 | ||
| Net loss attributable to the Pomdoctor Limited’s ordinary shareholders | (212,579,117) | (30,398,409) | (143,360,926) | (145,390,832) | ||
| Net loss | (130,931,921) | (18,723,015) | (37,365,434) | (36,949,421) | ||
| Other comprehensive loss: | ||||||
| Foreign currency translation adjustments, net of nil income taxes | (1,747,229) | (249,850) | (5,231) | |||
| Total comprehensive loss | (132,679,150) | (18,972,865) | (37,370,665) | (36,949,421) | ||
| Less: comprehensive income (loss) attributable to noncontrolling interests | (1,520) | (217) | 25,878 | 1,057 | ||
| Comprehensive loss attributable to the Pomdoctor Limited’s ordinary shareholders | ¥ (214,326,346) | $ (30,648,259) | ¥ (143,366,157) | ¥ (145,390,832) | ||
| Loss per share | ||||||
| Basic (in Dollars per share and Yuan Renminbi per share) | (per share) | ¥ (21.96) | $ (3.14) | ¥ (22.72) | ¥ (23.04) | ||
| Diluted (in Dollars per share and Yuan Renminbi per share) | (per share) | ¥ (21.96) | $ (3.14) | ¥ (22.72) | ¥ (23.04) | ||
| Weighted average number of ordinary shares outstanding* | ||||||
| Basic (in Shares) | [1] | 9,680,622 | 9,680,622 | 6,310,198 | 6,310,198 | |
| Diluted (in Shares) | [1] | 9,680,622 | 9,680,622 | 6,310,198 | 6,310,198 | |
| Third Parties | ||||||
| Net revenues | ¥ 399,359,702 | $ 57,107,678 | ¥ 341,328,781 | ¥ 304,729,898 | ||
| Related Party | ||||||
| Net revenues | ¥ 555,262 | $ 79,401 | ¥ 1,229,139 | ¥ 123,073 | ||
| ||||||
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in income from government assistance, classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expenses related to the generation of investment income. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of general expenses not normally included in Other Operating Costs and Expenses. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The aggregate total amount of expenses directly related to the marketing or selling of products or services. No definition available.
|
| X | ||||||||||
- Definition Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|